Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT ID: NCT05739435
Last Updated: 2025-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
165 participants
INTERVENTIONAL
2023-01-17
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
NCT05600036
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
NCT01537432
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESK-001 Dose Level 1
ESK-001 administered as an oral tablet
ESK-001
Oral tablet
ESK-001 Dose Level 2
ESK-001 administered as an oral tablet
ESK-001
Oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESK-001
Oral tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and Women must use highly effective methods of contraception for the entirety of the study
Exclusion Criteria
* Received a prohibited concomitant medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alumis Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigator Site # 1029
Birmingham, Alabama, United States
Investigator Site #1001
Phoenix, Arizona, United States
Investigator Site # 1023
Rogers, Arkansas, United States
Investigator Site #1021
Encinitas, California, United States
Investigator Site #1018
Los Angeles, California, United States
Investigator Site #1007
Santa Monica, California, United States
Investigator Site #1002
Sherman Oaks, California, United States
Investigator site # 1030
Fort Lauderdale, Florida, United States
Investigator Site #1025
Hialeah, Florida, United States
Investigator site # 1028
Miami, Florida, United States
Investigator Site # 1013
Tampa, Florida, United States
Investigator Site #1035
Macon, Georgia, United States
Investigator Site #1043
Sandy Springs, Georgia, United States
Investigator Site #1005
Rolling Meadows, Illinois, United States
Investigator Site # 1011
Columbus, Indiana, United States
Investigator Site #1027
South Bend, Indiana, United States
Investigator SIte#1036
Overland Park, Kansas, United States
Investigator Site #1017
Owensboro, Kentucky, United States
Investigator Site #1026
Rockville, Maryland, United States
Investigator Site #1010
Clarkston, Michigan, United States
Investigator Site #1031
New Brighton, Minnesota, United States
Investigator Site #1033
Norman, Oklahoma, United States
Investigator Site #1019
Portland, Oregon, United States
Investigator Site #1022
Philadelphia, Pennsylvania, United States
Investigator Site # 1012
Rapid City, South Dakota, United States
Investigator Site #1015
Houston, Texas, United States
Investigator Site # 1006
San Antonio, Texas, United States
Investigator Site # 1041
South Jordan, Utah, United States
Investigator Site #2001
Edmonton, Alberta, Canada
Investigator Site # 2008
Surrey, British Columbia, Canada
Investigator Site #2003
Winnipeg, Manitoba, Canada
Investigator Site #2006
London, Ontario, Canada
Investigator Site # 2004
Mississauga, Ontario, Canada
Investigator Site # 2007
North Bay, Ontario, Canada
Investigator Site #2005
Oakville, Ontario, Canada
Investigator Site #2009
Toronto, Ontario, Canada
Investigator Site # 2002
Waterloo, Ontario, Canada
Investigator Site # 2010
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESK-001-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.